100%, being less reliant on more CRs or partnerships in which we have to accept unfavourable terms are key benefits of having a revenue-generating product while we continue to develop our own.
We have very promising products under development and a high calibre board who knows how to take them through trials to market. Having cashflow to allow us choice and time in negotiating sales or partnerships puts us as a company in a much more favourable position than many.
There are plenty of research companies who have a product for commercialisation but few who are in a strong position to maximise the early value of its sale or licencing through a strong negotiating position.
BOT - Anything but charting, page-3592
-
- There are more pages in this discussion • 7,622 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.010(2.70%) |
Mkt cap ! $654.2M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 34.5¢ | $2.959M | 8.301M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 74186 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 422090 | 8 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |